Fundraising Overview - The company raised a total of RMB 1,483,482,000.00 through the issuance of 37,180,000 shares at a price of RMB 40.00 per share, with net proceeds after expenses amounting to RMB 1,378,838,926.21 [1][2] - As of June 30, 2025, the company has utilized RMB 1,102,682,065.36 of the raised funds, with RMB 103,363,523.27 used in the first half of 2025 [1][2] Fund Management - The company has established a fundraising management system in compliance with relevant laws and regulations to ensure effective use and management of the raised funds [1][2] - A tripartite supervision agreement has been signed with banks to regulate the storage and use of the funds, ensuring compliance with the regulations [1][2] Fund Utilization - The funds have been allocated primarily to innovation drug research and development (R&D) projects, with RMB 653,160,459.45 used for this purpose [1][2] - The company has also utilized RMB 429,759,485.91 for working capital and has temporarily set aside RMB 300,000,000.00 for cash management [1][2] Cash Management - The company has engaged in cash management using temporarily idle funds, with a maximum limit of RMB 80,000,000.00 approved for investment in safe and liquid financial products [3][4] - As of June 30, 2025, the company has invested RMB 300,000,000.00 in structured deposits and large-denomination certificates of deposit [7][8] Project Adjustments - The company has made adjustments to its fundraising projects, including the addition of two sub-projects under the "New Drug R&D Project" and the termination of the base project, reallocating unused funds to support R&D efforts [10][11] - The company has also decided to terminate the clinical development of a specific drug candidate, SY-1530, based on market assessments and resource allocation [10][11] Compliance and Reporting - The company has adhered to the regulatory requirements for fundraising and has disclosed the use and management of funds accurately and timely, with no violations reported [10][11]